Earlier today, the American Intellectual Property Law Association (AIPLA), Intellectual Property Owners Association (IPO), Licensing Executives Society (LES) International, LES USA & Canada, and New York Intellectual Property Association (NYIPLA) issued a joint statement expressing their concern regarding reports that the European Union, India, South Africa, and United States had reached a tentative compromise on a proposed TRIPS waiver of intellectual property rights (see "More on Leaked WTO COVID-19 Vaccine Patent Waiver Compromise"). The group indicated that they "strongly support equitable, widespread and successful distribution of vaccines necessary to meet the challenges of COVID-19," but argued that "the proposal currently being reported incorrectly portrays IP as a barrier to production and supply of COVID-19 vaccines," adding that they "know of no evidence to support that IP is such a barrier." Instead, the group cites a recent statement from the World Health Organization (WHO) that "there is enough [vaccine] supply to achieve our targets . . . [and that t]his is not a supply problem; it's an allocation problem." The group then suggests that "[s]olving the allocation problem is best accomplished by focusing on improvements to supply chain and distribution issues, rather than by concentrating on the red herring of intellectual property as an alleged barrier."